Home › NDC Lookup › RxCUI directory › RxCUI 2743019

24 HR ruxolitinib 22 MG Extended Release Oral Tablet — RxCUI 2743019

RxNorm drug concept · Semantic clinical drug
RxCUI 2743019 Semantic clinical drug · SCD ● Current RxNorm concept 10 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2743019
Official name24 HR ruxolitinib 22 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asruxolitinib 22 MG 24HR Extended Release Oral Tablet
FDA products mapped10
Package NDCs mapped11
Reported Medicaid activity (SDUD)8,082 prescriptions · 34 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ruxolitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Ruxolitinib targets overactive enzymes called JAK1 and JAK2 that are driving your condition — whether that's abnormal bone marrow cell growth in myelofibrosis or polycythemia vera,...
  • What exactly is ruxolitinib treating in my body?
  • Please don't stop suddenly without talking to your doctor first. If you stop ruxolitinib abruptly, your disease symptoms can come back quickly and sometimes more severely. If a sid...
  • Can I stop taking it if I feel better or if the side effects bother me?
📖 Read our full Ruxolitinib guide →

🕸️ Concept Web — How 24 HR ruxolitinib 22 MG Extended Release Oral Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR ruxolitinib 22 MG Extended Release Oral Tablet RxCUI 2743019

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ruxolitinib 1193326
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Jakafi 1193332
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ruxolitinib Extended Release Oral Tablet 2743011
    • Ruxolitinib Oral Product 1193328
    • Ruxolitinib Pill 1193329
    • Ruxolitinib Extended Release Oral Tablet [Jakafi] 2743015
    • Jakafi Oral Product 1193335
    • Jakafi Pill 1193336
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ruxolitinib 22 MG SCDC · 2743018
  • Ruxolitinib Extended Release Oral Tablet SCDF · 2743011
  • Ruxolitinib Oral Product SCDG · 1193328
  • Ruxolitinib Pill SCDG · 1193329

Brand-Name Concepts

📦 FDA Products & Package NDCs

10 products · 11 package NDCs
11 package NDCs map to RxCUI 2743019 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50881-0005-60 60 TABLET in 1 BOTTLE, PLASTIC (50881-005-60) JAKAFI Incyte Corporation 2011-11-16
50881-0010-01 28 TABLET in 1 BOTTLE, PLASTIC (50881-010-01) JAKAFI Incyte Corporation 2011-11-16
50881-0010-60 60 TABLET in 1 BOTTLE, PLASTIC (50881-010-60) JAKAFI Incyte Corporation 2011-11-16
50881-0011-08 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-011-... JAKAFI XR Incyte Corporation 2026-05-01
50881-0015-60 60 TABLET in 1 BOTTLE, PLASTIC (50881-015-60) JAKAFI Incyte Corporation 2011-11-16
50881-0020-60 60 TABLET in 1 BOTTLE, PLASTIC (50881-020-60) JAKAFI Incyte Corporation 2011-11-16
50881-0022-08 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-022-... JAKAFI XR Incyte Corporation 2026-05-01
50881-0025-60 60 TABLET in 1 BOTTLE, PLASTIC (50881-025-60) JAKAFI Incyte Corporation 2011-11-16
50881-0033-08 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-033-... JAKAFI XR Incyte Corporation 2026-05-01
50881-0044-08 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-044-... JAKAFI XR Incyte Corporation 2026-05-01
50881-0055-08 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50881-055-... JAKAFI XR Incyte Corporation 2026-05-01
Observed labelers: Incyte Corporation (11) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.